Navigation Links
New Cancer Treatment Stops Aggressive Sarcomas
Date:2/24/2009

NASHVILLE, Tenn., Feb. 25 /PRNewswire/ -- After all standard treatments had failed, a new cancer treatment has stopped the growth of aggressive sarcomas in two recent patients. These results are similar to the new protocol's previous success against several cancers, including melanoma, pancreatic, colon, mesothelioma and other sarcomas.

One of the patients is an 18-year-old with malignant fibrous histiocytoma (MFH) that arose in the largest bone of his leg. The cancer spread throughout his lungs, despite aggressive surgery that replaced most of his leg with metal implants. The second patient was losing a battle with desmoplastic small round cell tumor (DSRCT), a very rare and aggressive cancer. After undergoing multiple surgical procedures and different chemotherapy regimens, the DSRCT still progressed and spread through the abdomen.

After eight weeks of the NeoPlas regimen, scans showed that both patients' cancers had stopped their growth, and some tumors actually had regressed. Additionally, both patients are tolerating the treatment well and are able to carry on normal activities. NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell commented, "These are early results and not statistically valid yet. Still, the sarcomas as a group are so aggressive and uniformly fatal that being able to stop their growth and spread is very exciting. It's a major victory for these individuals, and it mirrors the success we're seeing in the great majority of patients so far." The protocol also is offered for qualifying patients with mesothelioma, colon cancer, renal (kidney) cancer, pancreatic cancer and melanoma.

This investigative treatment is a combination of lovastatin, typically used as a cholesterol lowering agent, and interferon. According to Dr. Cantrell, "The key to success has been starting with a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, tumors have begun regressing, sometimes within just a few weeks."

Fatigue is the most notable side effect of NeoPlas Innovation's cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment.

A web site, www.neoplas.org, provides answers to common questions and a screening tool. Individuals can reach NeoPlas Innovation at 615-371-8100.

    EDITORS' NOTE: For an interview with Dr. Cantrell, call 615-371-8100.

'/>"/>
SOURCE NeoPlas Innovation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
2. Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads
3. Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
4. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
5. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
6. Researchers Discover Metabolite Linked to Aggressive Prostate Cancer
7. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
8. Evidence Lacking in Multivitamin Study of Womens Risk of Cancer, Heart Disease or Death, Says Natural Products Association
9. deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
10. Breast Cancer Clinical Results Show Test Can Differentiate Normal, Early and Later Stage Cancers
11. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... ... ... – Monday, September 18 th .The Brain Tumor Foundation (BTF) begins ... the public.Where:  BTF,s Mobile MRI Unit – a ... Washington, D.C.What:BTF brings its nationwide initiative, the Road to Early Detection Sponsor-A-City ...
(Date:9/9/2017)... Lilly and Company (NYSE: LLY ) will ... an investigational, oral, first-in-class molecule for the acute treatment ... placebo in the Phase 3 SPARTAN study. Detailed results ... the International Headache Society (IHC) in Vancouver ... lasmiditan,s potential to reduce pain and provide freedom from ...
(Date:9/7/2017)... MIRAGE, Calif. , Sept. 7, 2017  For nearly two decades, ... service in the Assisted Reproduction Insurance industry. Today, New Life Agency announces ... fertility medications. ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ... ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... Silicon Valley ... even on the go. Their electric toothbrushes aggressively attack oral bacteria by reducing ... sanitizing technology. Combining leading edge Enke technology with a premium timeless design, they ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Letters From Home”: a moving ... lost, have value to God. “Letters From Home” is the creation of published author, ... the President’s Cabinet of Jerry Savelle Ministries International, who has traveled and ministered on ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... and create life. Although frozen embryos have a slight statistical advantage for live ... freezing is a wonderful opportunity for women undergoing medical treatment or who are ...
(Date:9/21/2017)... ... 21, 2017 , ... With ProSlideshow Portrait from Pixel Film Studios creating a ... select from up to two layers of subject matter along with fully customizable backdrop ... Final Cut Pro X. , With ProSlideshow Portrait each user are given ...
(Date:9/21/2017)... ... 21, 2017 , ... Process Capability Indices for Medical Device ... ET, http://www.fdanews.com/processcapabilityindices      , Quality in device manufacturing is ... Quality System Regulation (§820.250), and Devicemakers find themselves staring at a warning letter. ...
Breaking Medicine News(10 mins):